Rossari Biotech Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dqa0lyzdjrefeawhxwbiu7os.pdf

Key Takeaways


Volume Versus Price: The Quarter’s Tension

Menezes: "If you see the HPPC volumes, we have almost a 19% increase in volumes year on year, which overall is a very healthy trend for us. In the ARD also, we have a very healthy volume increase. It was only because of the price correction that happened that you see a small decrease in the HPPC sales."

Margin Strategy: Fill First, Then Lift

Menezes: "Our strategy is to fill our capacity; therefore, we are not looking at very high growth in margins. But we would like to keep the margins stable but fill capacity and therefore cost will come down and help us boost our EBITDA margins."

Subsidiary Integration: Tristar and Unitop


Exports: Cautious Now, Constructive Later


New Product Pipeline: Morpholine and Beyond

Menezes: "For the new products, there will always be a higher-margin idea. So, there is not going to be volume growth. I mean, we are not going to run after volumes over there."

Raw Material and Pricing Dynamics


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growthLow double-digit, 12% to 14%FY24
EBITDA marginAround 14%FY24
AHN segment growthGood growth expectedFY24
Unitop performanceStrong quarter ahead, 2,000+ tonne order book, 85-90%+ utilizationNear term
Export recoveryMaintain current run rate for 2 quarters, then grow post textile destockingH2 FY24
Tristar performanceGood annualized numbers expectedFY24

Key Metrics

MetricQ1 FY24
Revenue₹410.6 cr, compared to ₹406.5 cr in Q4 FY23 and ₹434.7 cr in Q1 FY23
EBITDA₹57.7 cr, compared to ₹54.6 cr in Q4 FY23 and ₹57.8 cr in Q1 FY23
EBITDA margin14.1%, up 70 bps QoQ and up 80 bps YoY
PAT₹29.2 cr, compared to ₹29 cr in Q4 FY23 and ₹28.7 cr in Q1 FY23
Consolidated volume growth~20% YoY
Consolidated revenue growth-6% YoY
HPPC volume growth19% YoY
Exports₹80 cr, roughly 20% of turnover; compared to ₹80 cr in Q4 FY23 and ~₹85 cr in Q1 FY23
Unitop capacity utilization85% to 90% plus in the last 3 months including July
Unitop pending ordersIn excess of 2,000 tonnes
Tristar stake acquisition cost₹16.9 cr for the remaining 16% stake, taking ownership to 100%
FY24 revenue growth guidance12% to 14%, management expects to achieve at least this post Q1 performance
FY24 EBITDA margin guidance~14%, management indicated this would be a good target